Heterologous Vaccine Schedule Against Sars-CoV-2 with 2 Doses of Inactivated Virus and a Booster of mRNA BNT162b2 in Kidney Transplant Recipients

M. Seija¹, F. Rammauro², J. Santiago¹, N. Orihuela³, C. Zulberti³, D. Machado⁴, C. Recalde⁴, J. Noboa¹, R. Astesiano¹, F. Yandian¹, A. Guerisoli¹, A. Morra³, D. Cassinelli¹, A. Pippolo¹, B. De Aramburu¹, C. Coelho¹, P. González¹, R. Romero¹, R. Rodriguez-Teja⁴, G. Acuña⁴, V. Rabaza⁴, N. Perg⁴, R. Cordero⁴, S. Orihuela³, L. Curi³, E. Burgstaller⁴, O. Noboa¹, O. Pritsch², M. Nin¹, S. Bianchi⁵

¹Centro de Nefrología, Hospital de Clínicas. Facultad de Medicina UdeLaR, Montevideo, Uruguay, ²Departamento de Inmunobiología, Facultad de Medicina, UdeLaR, Montevideo, Uruguay, ³Hospital Italiano, Montevideo, Uruguay, ⁴Hospital Evangélico, Montevideo, Uruguay, ⁵Departamento de Fisiopatología, Facultad de Medicina UdeLar, Montevideo, Uruguay

Meeting: 2022 American Transplant Congress

Abstract number: 978

Keywords: COVID-19, Kidney transplantation, Vaccination

Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)

Session Information

Session Name: All Infections (Excluding Kidney & Viral Hepatitis) II

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Emerging evidence suggests that 3 doses of SARS-CoV-2 mRNA vaccine enhance immunity in kidney transplant (KT) patients. However, few studies have focused on humoral response after inactivated virus-based vaccines. Here we report the results of humoral response in KT recipients in comparison with healthy control group after homologous and heterologous regimens with inactivated virus (Coronavac) and mRNA vaccine BNT162b2.

*Methods: A multicenter prospective study was conducted. KT recipients received heterologous vaccine schedule (2 doses of Coronavac and a booster of mRNA BNT162b2, n= 136) or homologous (3 doses of BNT162b2 n=19). Healthy control group received 2 doses or Coronavac (n=67) or BNT162b2 (n=15). Serum IgG antibodies against Receptor Binding Domain of SARS-CoV-2 Spike protein were determined 30 and 40 days after last dose.

*Results: Seroconversion was 52.2% and 57,9% with heterologous and homologous vaccination schedules in KT, p=0.789, figure 1. Among KT patients with seroconversion, antibody levels against RBD of SARS-CoV-2 were [1012 (183-3111) and 603 (41-1255) BAU/mL, with heterologous and homologous schedule, respectively. Levels were higher in KT compared to heathy control with 2 doses of inactivated virus 308 (209-335), p=0.03 and lower than heathy control with 2 doses of BNT162b2: 2638 (2608-3808) BAU/mL, p=0.001].

*Conclusions: Seroconversion improves after a third dose with homologous or heterologous vaccine schedules. Among patients with seroconversion antibody levels were higher than in heathy control with two doses of inactivated virus. Measurement of antibody levels could help to improve vaccination policies.

To cite this abstract in AMA style:

Seija M, Rammauro F, Santiago J, Orihuela N, Zulberti C, Machado D, Recalde C, Noboa J, Astesiano R, Yandian F, Guerisoli A, Morra A, Cassinelli D, Pippolo A, Aramburu BDe, Coelho C, González P, Romero R, Rodriguez-Teja R, Acuña G, Rabaza V, Perg N, Cordero R, Orihuela S, Curi L, Burgstaller E, Noboa O, Pritsch O, Nin M, Bianchi S. Heterologous Vaccine Schedule Against Sars-CoV-2 with 2 Doses of Inactivated Virus and a Booster of mRNA BNT162b2 in Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/heterologous-vaccine-schedule-against-sars-cov-2-with-2-doses-of-inactivated-virus-and-a-booster-of-mrna-bnt162b2-in-kidney-transplant-recipients/. Accessed November 21, 2024.

« Back to 2022 American Transplant Congress